Search Results - "GILL, JASVINDER"

Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs by Levin, Philip, MD, Zhou, Steve, PhD, Durden, Emily, PhD, Farr, Amanda M., MPH, Gill, Jasvinder, MD, Wei, Wenhui, PhD

“…Abstract Purpose In patients with type 2 diabetes mellitus (T2DM) not achieving glycemic targets using oral antidiabetes drugs (OADs), studies suggest that…”
Get full text

829-P: iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D) by Umpierrez, Guillermo, Gill, Jasvinder, Hood, David, Li, Xuan, Núñez, Ana

“…Introduction & Objective: Ethnic minorities and older adults, who are disproportionately affected by T2D, are underrepresented in studies. This retrospective…”
Get full text

Real-world outcomes in people with type 2 diabetes (PWD2) and renal impairment receiving insulin glargine 300 U/mL (Gla-300) and insulin degludec 100U/mL or 200U/mL (IDeg): the DELIVER-R study by Bailey, Timothy, Urquhart, Scott, Westerbacka, Jukka, Gill, Jasvinder, Nicholls, Charlie

Get full text

An exploratory analysis of the cost‐effectiveness of insulin glargine 300units/mL versus insulin glargine 100units/mL over a lifetime horizon using the BRAVO diabetes model by Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Abdul Jabbar Omar Alsaleh, Gill, Jasvinder, Nicholls, Charlie

“…BackgroundThis analysis assessed the cost‐effectiveness of insulin glargine 300 units/mL (Gla‐300) versus insulin glargine 100 units/mL (Gla‐100) in…”
Get full text

An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model by Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Alsaleh, Abdul Jabbar Omar, Gill, Jasvinder, Nicholls, Charlie

“…This analysis assessed the cost-effectiveness of insulin glargine 300 units/mL (Gla-300) versus insulin glargine 100 units/mL (Gla-100) in insulin-naïve adults…”
Get full text

Cost‐effectiveness analysis of once‐daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model by Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Alsaleh, Abdul Jabbar Omar, Gill, Jasvinder, Nicholls, Charlie

“…Aims A cost‐effectiveness analysis was conducted to compare insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in insulin‐naïve…”
Get full text

Cost‐effectiveness analysis of once‐daily insulin glargine 300U/mL versus insulin degludec 100U/mL using the BRAVO diabetes model by Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Abdul Jabbar Omar Alsaleh, Gill, Jasvinder, Nicholls, Charlie

“…AimsA cost‐effectiveness analysis was conducted to compare insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in insulin‐naïve…”
Get full text

103-LB: Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1 by WRIGHT, EUGENE, GILL, JASVINDER, HUSE, SAMUEL, LI, XUAN, REID, TIMOTHY, ZHOU, FANG L.

“…This retrospective observational study using the Optum Clinformatics claims database included data from adults (≥18 y) with T2D who had received prior basal…”
Get full text

Real‐world outcomes of addition of insulin glargine 300U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study by Bailey, Timothy S, Gill, Jasvinder, Jones, Merwyn, Shenoy, Laxmi, Nicholls, Charlie, Westerbacka, Jukka

“…AimsTo provide real‐world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon‐like…”
Get full text

1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S by MENEGHINI, LUIGI, CHENG, ALICE, EVENOU, PIERRE, GILL, JASVINDER, MOHAMED, AYAD, UMPIERREZ, GUILLERMO E.

“…In the 12-month ACHIEVE Control study, significantly more insulin-naive patients with T2D treated with Gla-300 vs. SOC-BI (glargine 100 U/mL or detemir)…”
Get full text

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study by BAILEY, TIMOTHY S., WESTERBACKA, JUKKA, NICHOLLS, CHARLIE, GILL, JASVINDER, JONES S, MERWYN, SHENOY, LAXMI

“…In PWD2 inadequately controlled with GLP-1 RA therapy, addition of basal insulin is recommended. We used a US electronic medical record data source (IBM…”
Get full text

Insulin glargine 300 U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial by Meneghini, Luigi, Blonde, Lawrence, Gill, Jasvinder, Dauchy, Arnaud, Bacevicius, Andrius, Strong, Jodi, Bailey, Timothy S.

“…Aim To report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the…”
Get full text

Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control by Anderson, John, Meneghini, Luigi, Hinnen, Debbie, Gill, Jasvinder, Coudert, Mathieu, Evenou, Pierre, Munshi, Medha

“…To better understand outcomes in people with type 2 diabetes at high risk of hypoglycemia, we conducted post hoc analyses in subgroups of participants from the…”
Get full text

812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU), and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1st-Gen) BI (Glargine 100 U/mL [Gla-100] or Detemir [IDet 100 U/mL]) by EDELMAN, STEVEN, GOLDMAN, JENNIFER D., MALONE, DANIEL C., PREBLICK, RON, MUNAGA, KOVIDA, LI, XUAN, GILL, JASVINDER, GANGI, SUMANA

“…This retrospective observational analysis of the Optum Clinformatics database compared outcomes for adults (≥18y) with T2D who either continued treatment with…”
Get full text

Insulin glargine 300U/mL versus first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 12‐month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real‐life clinical trial by Meneghini, Luigi, Blonde, Lawrence, Gill, Jasvinder, Dauchy, Arnaud, Bacevicius, Andrius, Strong, Jodi, Bailey, Timothy S

“…AimTo report the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) versus standard‐of‐care basal insulin analogues (SOC‐BI) at 12 months in the…”
Get full text

Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study by Bailey, Timothy S., Gill, Jasvinder, Jones S., Merwyn, Shenoy, Laxmi, Nicholls, Charlie, Westerbacka, Jukka

“…Aims To provide real‐world data on the addition of basal insulin (BI) in people with type 2 diabetes mellitus (PWD2) suboptimally controlled with glucagon‐like…”
Get full text

1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study by MENEGHINI, LUIGI, GILL, JASVINDER, DAUCHY, ARNAUD, BACEVICIUS, ANDRIUS, STRONG, JODI, BAILEY, TIMOTHY S.

“…ACHIEVE Control, a pragmatic randomized real-world clinical trial, prospectively compared the effectiveness and safety of Gla-300 vs. SoC-BIs (glargine 100…”
Get full text

Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring by Pettus, Jeremy, Gill, Jasvinder, Paranjape, Sachin, Stewart, John, Malla, Shilpy, Edelman, Steven, Bergenstal, Richard M., Bode, Bruce

“…Video : View a video  for this article. Aims This multicentre (N = 104), randomized controlled phase 4 study compared the efficacy and safety of insulin…”
Get full text

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100) by Edelman, Steven, Goldman, Jennifer, Malone, Daniel C, Preblick, Ronald, Munaga, Kovida, Li, Xuan, Gill, Jasvinder, Gangi, Sumana

“…People with type 2 diabetes receiving a second-generation basal insulin (BI) analog may be switched to a first-generation formulation for financial reasons or…”
Get full text

A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first‐generation basal insulin analogues in insulin‐naïve adults with type 2 diabetes: 6‐month outcomes of the ACHIEVE Control study by Meneghini, Luigi F., Sullivan, Sean D., Oster, Gerry, Busch, Robert, Cali, Anna M. G., Dauchy, Arnaud, Gill, Jasvinder, Bailey, Timothy S.

“…Aims To compare the safety and efficacy of insulin glargine 300 U/mL (Gla‐300) versus first‐generation standard‐of‐care basal insulin analogues (SOC‐BI;…”
Get full text